DIFFERENCE IN TREATMENT OUTCOMES ACCORDING TO OPTICAL COHERENCE TOMOGRAPHY-BASED STAGES IN TYPE 3 NEOVASCULARIZATION (RETINAL ANGIOMATOUS PROLIFERATION)

Optical Coherence Tomography, Neovascularization , Retinal Angiomatous Proliferation

2017 Oct 10. doi: 10.1097/IAE.0000000000001876. [Epub ahead of print]

DIFFERENCE IN TREATMENT OUTCOMES ACCORDING TO OPTICAL COHERENCE TOMOGRAPHY-BASED STAGES IN TYPE 3 NEOVASCULARIZATION (RETINAL ANGIOMATOUS PROLIFERATION).

Abstract

PURPOSE:

To compare 12-month treatment outcomes of Type 3 neovascularization among its different stages as classified using an optical coherence tomography-based method.

METHODS:

This retrospective observational study included 40 patients (40 eyes) who were newly diagnosed with Type 3 neovascularization. The patients were initially administered 3 monthly anti-vascular endothelial growth factor injections. Repeat treatment was performed when recurrence of fluid was noted. Disease staging was classified using the optical coherence tomography-based method. The best-corrected visual acuity at diagnosis and at 12 months and degree of change in best-corrected visual acuity were compared among the different stages of the disease. In addition, incidence of progression in the disease stages was estimated.

RESULTS:

Among the 40 patients, 14 (35.0%) were classified as Stage 2 and 26 (65.0%) were classified as Stage 3. The best-corrected visual acuity values at diagnosis and at 12 months were 0.61 ± 0.31 (20/81 Snellen equivalents) and 0.46 ± 0.30 (20/57) in the Stage 2 group and 0.67 ± 0.42 (20/93) and 0.70 ± 0.49 (20/100) in the Stage 3 group, respectively. There was a significant difference in best-corrected visual acuity change between the two groups (P = 0.036). During the follow-up period, 3 retinal pigment epithelium tears and 2 submacular hemorrhages had developed in the Stage 3 group. Progression of the disease from Stage 2 to Stage 3 was noted in 2 patients (14.3%).

CONCLUSION:

The visual outcome was worse in Stage 3 than in Stage 2, and adverse events that may lead to abrupt visual deterioration developed only in Stage 3. Further studies are needed to reveal whether anti-vascular endothelial growth factor therapy can suppress the progression of the disease stages.

Optical Coherence Tomography, Neovascularization , Retinal Angiomatous Proliferation

PMID:
29019795
DOI:
10.1097/IAE.0000000000001876

Comparison of central corneal thickness with four different optical devices

corneal thickness, optical devices

2017 Oct 11. doi: 10.1007/s10792-017-0736-7. [Epub ahead of print]

Comparison of central corneal thickness with four different optical devices.

Abstract

BACKGROUND:

To compare the consistency between the average scores of the contact central corneal thickness measurements from ultrasound pachymetry devices still gold standard, such as iPac® and Echoscan US-500, and noncontact measurements via Pentacam HR and Sirius topography.

METHODS:

This prospective study, subsequently admitted to the ophthalmology department, 76 healthy individuals were performed. The measurements were repeated three times for each eye, and average scores were statistically analyzed on the same day and almost at the same time. While measuring the eyes, Pentacam HR, Sirius topography, iPac®, and Echoscan US-500 were used, respectively. The inter-rater agreement of measurements from the devices was assessed with intraclass correlation coefficient, and 95% Confidence Interval and p values demonstrating statistically significance were also presented. In the graphical assessment of the agreement, the Bland-Altman graph was used.

RESULTS:

Among 76 study participants, 43 (56.6%) were composed of women, and age level was 38.6 ± 12.5 years, ranging between 18 and 69. It was observed that the highest agreement was between the measurements obtained from Echoscan US-500 and iPac® devices, but the agreement between the measurements of different devices was higher than 0.90. Bland-Altman graphics were also investigated; the results of four different devices were seen to be consistent with one another.

CONCLUSIONS:

Therefore, the devices we compared in the study can be used as alternatives to one another due to the higher consistency between CCT measurements provided with through UP devices of Echoscan US-500 and iPac®, and Pentacam HR and Sirius topography devices.

CLINICAL TRIAL REGISTRATION NUMBER:

2016/112.

corneal thickness, optical devices

KEYWORDS:

Central corneal thickness; ,®

PMID:
29022163
DOI:
10.1007/s10792-017-0736-7